Home
Biorecognition

News archive for Biorecognition

Read about druggabily predictions for RNA targets, the current state of fragment-based drug discovery for RNA, and an experimental toolbox to push drug discovery for antibiotics.
Vipul has presented an update of our JPIAMR EXPLOR project on a recent JPIAMR workshop (25:55 to 38:02)
An Experimental Toolbox for Structure-Based Hit Discovery for P. Aeruginosa FabF, a Promising Target for Antibiotics
A new study from the University in Bergen may shed light on the comorbidities found in adults suffering from this rare disease.
Researchers at the Department of Biomedicine focus on large RNA structures in bacteria as a target for new antibiotics. Read the latest review article on riboswitches.
The Biorecognition Unit wants to wish everyone a Merry Christmas and a Happy New Year! :-)
Congratulations to Illimar who got the price for the second best oral presentation at the 34. Molecular Modeling Workshop 2020 in Erlangen. Well done!
An important European-funded initiative has been launched to explore how common molecular mechanisms may link metabolic disorders, especially type 2 diabetes and obesity, with brain disorders such as Alzheimer's disease, obsessive-compulsive disorder, and autism spectrum disorders. Jan Haavik and Aurora Martinez from the Department of Biomedicine are the norwegian participants.
Martinez and collaborators are developing a pharmacological chaperone therapy for acute intermittent porphyria
Researchers from the Department of Biomedicine describe the atomic details responsible for the short length of actin filaments in the malaria parasite.
The Nor-Openscreen application for this year's infrastructure call scored the highest possible marks in all categories! To quote from the reviewer comments: "This is an excellent proposal to enlarge and update existing infrastructure and services in chemical biology in Norway". Despite the very favorable evaluation, the proposal was not funded. This means, there will unfortunately... Read more
Our new paper on entangling selectivity determining features and on how to use this knowledge to design selective ligands has been published in J Med Chem!
The structure of full-length phenylalanine hydroxylase in complex with the cofactor BH4 is presented in the most recent issue of PNAS. As the cofactor is also used as a therapy for PKU, this structure is of medical importance.
Researchers from the lab of Aurora Martinez describe a novel mechanism for the degradation of enzymes involved in phenylketonuria and other neurometabolic disorders.

Pages